I loved this talk, mostly because I am marrying it with a talk done by Nima Mesbah Ardakani on the different mutations in spitzoid lesions (January '21) and there are now so many updates that the line between benign and malignant is blurred terribly (especially with ROS1, Braf fusion and Map3k8 fusion tumours). Your ferrari comment made us all laugh, looking forward to the long awaited books arriving in the next few days.
Very helpful! Thanks.
I loved this talk, mostly because I am marrying it with a talk done by Nima Mesbah Ardakani on the different mutations in spitzoid lesions (January '21) and there are now so many updates that the line between benign and malignant is blurred terribly (especially with ROS1, Braf fusion and Map3k8 fusion tumours). Your ferrari comment made us all laugh, looking forward to the long awaited books arriving in the next few days.
Thank you!
Thank you!!!